Warttig S, Alderson P, Campbell G, Smith AF. Interventions for treating inadvertent postoperative hypothermia. Cochrane Database Syst Rev. 2014 Nov 20;11:CD009892. doi: 10.1002/14651858.CD009892.pub2
Hogue SL, Bjoerk B, Walker A, Balp M, Fernandez MM, Quijano M, Ling CS, Heyes AE. Evidence-based market access value resource: navigating the hurdles for a biologic obtaining a license in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam. [abstract] Value Health. 2014 Nov; 17(7):A431-2.
Mahida S, Algarni M, Rittenhouse B. Effect of excluding non-patient benefits as an element on Acmg newborn screening (Nbs) recommendations. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 11, 2014. Amsterdam, Netherlands. [abstract] Value Health. 2014 Nov 1; 17(7):PA541. doi: 10.1016/j.jval.2014.08.1739
Novick D, Montgomery W, Aguado J, Duenas H, Haro JM. Symptomatic factors in patients with major depressive disorder (MDD): results from an observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A543.
Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Comparative effectiveness in terms of treatment discontinuation of orodispersable versus standard oral olanzapine tablets in non-adherent patients: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A766.
Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A455.
Herring WL, Pearson IV, Purser MF, Nakhaipour HR, Haiderali A, Wolowacz SE, Jayasundara K. Cost-effectiveness of ofatumumab plus chlorambucil in first line chronic lymphocytic leukemia in Canada. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):PA633.
Basarir H, Pollard D, Brennan A, Elliott J, Heller S, Campbell MJ. The potential value of ongoing support in type-1 diabetes mellitus with dafneplus: exploratory pre-trial cost-effectiveness analysis on proposed trial end-point target for 12-month Hba1c improvement. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A350. doi: 10.1016/j.jval.2014.08.725
Vass CM, Rigby D, Campbell S, Payne K. Investigating the framing-effects of risk attributes in discrete choice experiments: a pilot study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A648. doi: 10.1016/j.jval.2014.08.2349
McLeod L. Review of the Task Force Report on PRO data collection in clinical trials using mixed modes. Value Health. 2014 Jul;17(5):491-2. doi: 10.1016/j.jval.2014.06.003
Alderson P, Campbell G, Smith AF, Warttig S, Nicholson A, Lewis SR. Thermal insulation for preventing inadvertent perioperative hypothermia. Cochrane Database Syst Rev. 2014 Jun 4;6:CD009908. doi: 10.1002/14651858.CD009908.pub2
Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nelson LM, McLeod LD, Mordin M, Gottlieb A, Elewski B, Lebwohl MG. Psychometric evaluation of the Psoriasis Symptom Diary using phase 3 trial data. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 Jun; 17(3):A288. doi: 10.1016/j.jval.2014.03.1676
Hartley L, Dyakova M, Holmes J, Clarke A, Lee MS, Ernst E, Rees K. Yoga for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014 May 13;5:CD010072.
Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.
Parikh R, Taychakhoonavudh S, White C, Franzini L. Sources of spending variation in professional services among Texas Hospital Referral Regions: an analysis of private insurance population. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A18. doi: 10.1016/j.jval.2014.03.116
Hauber AB, Nguyen H, Posner JD, Ervin CM, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (glp-1ra) injections in the treatment of type 2 diabetes. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A255.
Schwab PE, Saundankar V, Bouchard J, Moretz C, Baltz J. Delayed treatment modifications for patients with type 2 diabetes mellitus with very poor glycemic control. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 31, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3).
Ramamohan V, Mladsi DM, Kaye JA, Boey W, Pozzi R. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A87.
Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355
Lewis S, Price M, Dwyer KA, O'Brien S, Heekin RD, Yates PJ, Beverland D, Mordin M. Development of a scale to assess performance following primary total knee arthroplasty. Value Health. 2014 Apr 21;17(4):350-9. doi: 10.1016/j.jval.2014.01.006
Hartley L, Flowers N, Lee MS, Ernst E, Rees K. Tai chi for primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014 Apr 9;4:CD010366. doi: 10.1002/14651858.CD010366
Al-Khudairy L, Hartley L, Clar C, Flowers N, Hooper L, Rees K. Omega 6 fatty acids for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014 Apr;11:CD011094. doi: 10.1002/14651858.CD011094.pub2
Lairson DR, Parikh RC, Cormier JN, Du XL. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Value Health. 2014 Feb;17(1):34-42.
Flowers N, Hartley L, Todkill D, Stranges S, Rees K. Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;12:CD010405. doi: 10.1002/14651858.CD010405
DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value Health. 2013 Dec;16(8):1150-5. doi: 10.1016/j.jval.2013.08.2293
von Scheele B, Mauskopf J, Brodtkorb T, Ainsworth C, Galani Berardo C, Patel A. Relationship between modelling approach and reported outcomes: case studies of models for the treatment of schizophrenia. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A589.
Wolowacz S, Brockbank J, Sunderland TJ, Gonschior AK. Cost-effectiveness of dabigatran etexilate for the secondary prevention of recurrent deep vein thrombosis and pulmonary embolism in the United Kingdom. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A526.
Stull DE, McBride D, Gnanasakthy A, Balp M. Correlations between changes in the urticaria activity score (UAS7) and the dermatology life quality index (DLQI) from baseline to 28 or 40 weeks: comparisons of trajectories of change in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A509.
Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: methods used in recent economic evaluations. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A579.
Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: an overview of cost, utility, and cost-effectiveness data. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.
Wilburn J, McKenna S, Twiss J, Kemp K, Campbell S. Validation of the Crohn's Life Impact Questionnaire (CLIQ), the first patient-reported outcome measure specific to adults with Crohn's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A499-500. doi: 10.1016/j.jval.2013.08.1129
Wilburn J, McKenna S, Twiss J, Kemp K, Campbell S. Validating the Unidimensional Fatigue Impact Scale (U-FIS) for use in Crohn's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A499. doi: 10.1016/j.jval.2013.08.1128
Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.
Davis KL, Candrilli S. Recent trends in hospital costs, length of stay, and mortality associated with pediatric meningococcal disease in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.
Davis KL, Candrilli S. Recent trends in incidence and demographics of pediatric meningococcal disease in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A342.
Twiss J, McKenna S, Graham JE, Swetz KM, Sloan J, Gomberg-Matiland M. Assessing measurement equivalence of different forms of administration of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) using Rasch analysis. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A606. doi: 10.1016/j.jval.2013.08.1731
Twiss J, McKenna S, Rouse M. Using Rasch analysis to co-calibrate scores from outcome measures specific to asthma (ALIS), chronic obstructive pulmonary disease (LCOPD) and pulmonary hypertension (CAMPHOR). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A605. doi: 10.1016/j.jval.2013.08.1724
Marcano Belisario JS, Huckvale K, Greenfield G, Car J, Gunn LH. Smartphone and tablet self management apps for asthma. Cochrane Database Syst Rev. 2013 Nov;2013(11):CD010013. doi: 10.1002/14651858.CD010013.pub2
Hogue S, Scott A, van Amerongen D, Hollis K, McLeod L, Brogan A. Payer and decision maker use of observational studies for health care reimbursement decisions. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 Nov; 16(7):A459-60.
Bhattacharyya S, Sacco P, Shirore R, Sonathi V, Thomas SK. A de novo economic model to assess the cost and quality of life consequences of an intervention for levodopa induced dyskinesia amongst patients with Parkinson's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A590-1.
Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.
Rycroft C, Fernandez M, Copley-Merriman K. Systematic literature reviews at the heart of health technology assessment: a comparison across markets. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A481.
Raspa M, Bishop E, Candrilli S, Mitra D, Sacco P, Petrillo J, Bailey D. US caregiver burden in Fragile X syndrome as a function of a health-state utility index. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A625.
Korsnes JS, Goodwin BB, Candrilli SD. The association between adherence to antiretroviral therapy and economic outcomes among commercially insured and medicaid hiv patients in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A348-9.
Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Factors associated with pain persistence in patient with depression during a 3-month follow-up period. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Amsterdam, The Netherlands. [abstract] Value Health. 2013 Nov; 16(7):A544.
Ara R, Basarir H, Keetharuth A, Weatherly H, Barbieri M, Sculpher MJ. Economic evidence of surgical procedures in cancer: a systematic literature review. Poster presented at the 2013 ISPOR 16th Annual European Congress; October 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A411. doi: 10.1017/S0266462314000531
Rouse M, McKenna S, Twiss J, Graham JE, Wilburn J. Quality of life outcomes in multiple sclerosis: a review of the literature. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A626. doi: 10.1016/j.jval.2013.08.1843
Graham JE, McKenna S, Wilburn J, Twiss J. Assessing quality of life in adult growth hormone deficiency: further development of the QoL-AGHDA. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A446-7. doi: 10.1016/j.jval.2013.08.710
Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226
Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M, Stranges S. 'Mediterranean' dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Aug 12;8:CD009825. doi: 10.1002/14651858.CD009825